News Sections
Audio
Eli Lilly Alzheimer's Drug Fails In Latest Clinical Study
Updated November 24, 2016 7:47 AM | Filed under: Health
 Print    Archive    RSS

(INDIANAPOLIS) - Eli Lilly's Alzheimer's treatment failed in a large clinical study, ending hope that researchers had finally found a drug that can slow the fatal, mind-robbing disease.

The drug company's shares plunged 13 percent before the opening bell Wednesday.

The drug, solanezumab, missed the study's main goal of significantly slowing cognitive decline in patients compared to a placebo or fake drug.

Eli Lilly and Co. had been studying the drug in patients with mild cases of the disease.

Current Alzheimer's treatments like Aricept and Namenda only temporarily ease symptoms such as memory loss, confusion and agitation. They don't slow, stop or reverse the mental decline that happens when the brain's nerve cells stop functioning normally.

At least 18 other drugs are in late-stage testing, including several similar to solanezumab.



« Previous Article
Next Article »

 Print    Archive    RSS

Have a question or comment about a news story? Send it to comments@wbiw.com

Advertise with 1340 AM WBIW
Find more about Weather in Bedford, IN
Advertise with 1340 AM WBIW


1340 AM WBIW, Bedford's Place To Talk. Serving Lawrence and surrounding counties since 1948!

© 2017 Ad-Venture Media, Inc. All Rights Reserved.   WBIW.com and Listen Live Powered by HPC

Advertise  |  Careers  |  Contests  |  About  |  Feedback